ReviewMetabolites2025
Serum Uric Acid in the PAMELA Study: Main Findings and Association with the Atherogenic Index of Plasma.
Review in Metabolites, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between atherogenic index of plasma and various metabolic conditions: an umbrella review on meta-analyses.BMC cardiovascular disorders · 2025Pooled it
- Atherogenic Index of Plasma as Predictor for Cardiovascular Events and Cardiometabolic Diseases:Findings from the PAMELA Study.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum uric acid (SUA) overproduction, leading to hyperuricemia, represents a metabolic dysfunction of frequent detection in a number of diseases characterized by an elevated cardiovascular risk, such as metabolic syndrome, essential hypertension, dyslipidemia, obesity, and diabetes mellitus. Similar findings have been also reported for the Atherogenic Index of Plasma (AIP), i.e., a biomarker derived from the logarithmic transformation of the ratio between plasma triglycerides and high-density plasma lipoprotein cholesterol. Both SUA and AIP have been found to be sensitive predictors of fatal and non-fatal cardiovascular events and all-cause mortality, their association representing a highly sensitive marker potentiating the predictive value of each single factor. Although a number of studies have investigated the relationships between SUA and AIP, the association between these two metabolic variables still remains in several indistinct aspects. The present paper, after briefly summarizing the main features of the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study, will review the main study results related to SUA as cardiovascular risk factors. It will also report the original data collected in the PAMELA study on (1) the association between SUA and AIP and (2) the relationships between AIP and normal and elevated blood pressure, metabolic profile, and target organ damage associated with hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.